Cargando…

A Multifactorial Mechanism in the Superior Antimalarial Activity of α-C-GalCer

We have previously shown that the C-glycoside analog of α-galactosylceramide (α-GalCer), α-C-GalCer, displays a superior inhibitory activity against the liver stages of the rodent malaria parasite Plasmodium yoelii than its parental glycolipid, α-GalCer. In this study, we demonstrate that NK cells,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schmieg, John, Yang, Guangli, Franck, Richard W., Tsuji, Moriya
Formato:	Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2010
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2801455/ https://www.ncbi.nlm.nih.gov/pubmed/20069056 http://dx.doi.org/10.1155/2010/283612

Ejemplares similares

Synthesis of a 2''-Deoxy-β-GalCer
por: Thakur, Meena S., et al.
Publicado: (2014)

Interaction between Bacteria and the Immune System for Cancer Immunotherapy: The α-GalCer Alliance
por: Ustjanzew, Arsenij, et al.
Publicado: (2022)

α-GalCer and iNKT Cell-Based Cancer Immunotherapy: Realizing the Therapeutic Potentials
por: Zhang, Yingting, et al.
Publicado: (2019)

Galactosylsphingamides: new α-GalCer analogues to probe the F’-pocket of CD1d
por: Guillaume, Joren, et al.
Publicado: (2017)

6″-Modifed α-GalCer-peptide conjugate vaccine candidates protect against liver-stage malaria
por: Meijlink, Michael A., et al.
Publicado: (2022)

Thermodynamic and Structural Behavior of α‐Galactosylceramide and C6‐Functionalized α‐GalCer in 2D Layers at the Air–Liquid Interface
por: Brezesinski, Gerald, et al.
Publicado: (2019)

Superior Protection against Malaria and Melanoma Metastases by a C-glycoside Analogue of the Natural Killer T Cell Ligand α-Galactosylceramide
por: Schmieg, John, et al.
Publicado: (2003)

Modulation of NKT cells and Th1/Th2 imbalance after α-GalCer treatment in progressive load-trained rats
por: Ru, Wang, et al.
Publicado: (2009)

Encapsulation of MERS antigen into α-GalCer-bearing-liposomes elicits stronger effector and memory immune responses in immunocompetent and leukopenic mice
por: Khan, Masood Alam, et al.
Publicado: (2022)

Tumor-Localized Administration of α-GalCer to Recruit Invariant Natural Killer T Cells and Enhance Their Antitumor Activity against Solid Tumors
por: Li, Yan-Ruide, et al.
Publicado: (2022)

A Glycolipid α-GalCer Derivative, 7DW8-5 as a Novel Mucosal Adjuvant for the Split Inactivated Influenza Vaccine
por: Feng, Huapeng, et al.
Publicado: (2022)

Immunomodulatory Cell Therapy Using αGalCer-Pulsed Dendritic Cells Ameliorates Heart Failure in a Murine Dilated Cardiomyopathy Model
por: Ikeda, Masataka, et al.
Publicado: (2022)

Immune Modulating Effects of NKT Cells in a Physiologically Low Dose Leishmania major Infection Model after αGalCer Analog PBS57 Stimulation
por: Griewank, Klaus G., et al.
Publicado: (2014)

Crystal Structures of Bovine CD1d Reveal Altered αGalCer Presentation and a Restricted A’ Pocket Unable to Bind Long-Chain Glycolipids
por: Wang, Jing, et al.
Publicado: (2012)

Repeated α-GalCer Administration Induces a Type 2 Cytokine-Biased iNKT Cell Response and Exacerbates Atopic Skin Inflammation in Vα14(Tg) NC/Nga Mice
por: Park, Hyun Jung, et al.
Publicado: (2021)

A Designed α‐GalCer Analog Promotes Considerable Th1 Cytokine Response by Activating the CD1d‐iNKT Axis and CD11b‐Positive Monocytes/Macrophages
por: Ma, Juan, et al.
Publicado: (2020)

A randomized phase II study to assess the effect of adjuvant immunotherapy using α-GalCer-pulsed dendritic cells in the patients with completely resected stage II–IIIA non-small cell lung cancer: study protocol for a randomized controlled trial
por: Saka, Hideo, et al.
Publicado: (2017)

The α-Gal Syndrome and Potential Mechanisms
por: Román-Carrasco, Patricia, et al.
Publicado: (2021)

Comparative Effectiveness Research (CER): A Summary of AHRQ’s CER on Therapies for Rheumatoid Arthritis
por: Oderda, Gary M., et al.
Publicado: (2011)

Biosynthesis of α-Gal Epitopes (Galα1-3Galβ1-4GlcNAc-R) and Their Unique Potential in Future α-Gal Therapies
por: Galili, Uri
Publicado: (2021)

Implementing CER: What Will It Take?
por: Biskupiak, Joseph E., et al.
Publicado: (2012)

Conversion of Tumors into Autologous Vaccines by Intratumoral Injection of α-Gal Glycolipids that Induce Anti-Gal/α-Gal Epitope Interaction
por: Galili, Uri
Publicado: (2011)

CerS1 but Not CerS5 Gene Silencing, Improves Insulin Sensitivity and Glucose Uptake in Skeletal Muscle
por: Błachnio-Zabielska, Agnieszka U., et al.
Publicado: (2022)

Course of IgE to α‐Gal in a Swedish population of α‐Gal syndrome patients
por: Apostolovic, Danijela, et al.
Publicado: (2021)

Patient engagement – the PaCER model
por: Hylton, Chris
Publicado: (2015)

Non-clinical development of CER-001
por: Barbaras, Ronald
Publicado: (2015)

Nursing Research, CER, PICO and PCORI
por: Patel, Darpan I
Publicado: (2017)

Looking at CER from Medicare’s Perspective
por: Mohr, Penny
Publicado: (2012)

Immune Responses to Pandemic H1N1 Influenza Virus Infection in Pigs Vaccinated with a Conserved Hemagglutinin HA1 Peptide Adjuvanted with CAF(®)01 or CDA/αGalCerMPEG
por: López-Serrano, Sergi, et al.
Publicado: (2021)

Study on CerAMfacturing of Novel Alumina Aerospike Nozzles by Lithography-Based Ceramic Vat Photopolymerization (CerAM VPP)
por: Schwarzer-Fischer, Eric, et al.
Publicado: (2022)

CsCER6 and CsCER7 Influence Fruit Glossiness by Regulating Fruit Cuticular Wax Accumulation in Cucumber
por: Liu, Xiaofeng, et al.
Publicado: (2023)

IgE, α-Gal and atherosclerosis
por: Wilson, Jeffrey M., et al.
Publicado: (2019)

Looking at CER from the Pharmaceutical Industry Perspective
por: Dubois, Robert W.
Publicado: (2012)

Acceleration of Wound Healing by α-gal Nanoparticles Interacting with the Natural Anti-Gal Antibody
por: Galili, Uri
Publicado: (2015)

Bivalent non-human gal-α1-3-gal glycan epitopes in the Fc region of a monoclonal antibody model can be recognized by anti-Gal-α1-3-Gal IgE antibodies
por: Hatfield, Grayson, et al.
Publicado: (2023)

cGAL, a Temperature-Robust GAL4-UAS System for C. elegans
por: Wang, Han, et al.
Publicado: (2016)

Characteristics of α-Gal epitope, anti-Gal antibody, α1,3 galactosyltransferase and its clinical exploitation (Review)
por: HUAI, GUOLI, et al.
Publicado: (2016)

Poly-L-Lysine-Based αGal-Glycoconjugates for Treating Anti-αGal IgE-Mediated Diseases
por: Olivera-Ardid, Sara, et al.
Publicado: (2022)

Th2-skewed T cells correlate with B cell response to α-Gal and tick antigens in α-Gal syndrome
por: Apostolovic, Danijela, et al.
Publicado: (2023)

Abundant human anti-Galα3Gal antibodies display broad pathogen reactivity
por: Bernth Jensen, Jens Magnus, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_vooms0jghb7qt1h4jsbhh8dlog